Food and Drug Administration The agency has issued warning letters to stop the distribution of illegally marketed semaglutide, saying the drugs may be counterfeit, which means they could contain the wrong ingredients, contain too little, too much or no active ingredient at all, or contain other harmful ingredients. In July, it said that it had received reports of dosing errors with compounded semaglutide injectable products, some of which landed patients in the hospital
Rarely, patients may experience palpitations or perceive the increased heart rate, though these symptoms usually do not require treatment discontinuation
However, start graduallynausea and reduced appetite can make high-intensity work risky early on
Medical monitoring helps to assess the patient's response to the medication, identify potential side effects or adverse reactions, and make necessary adjustments to the dosage
Lacks transparency regarding the pricing